Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Palantir Fixed Tech100 Index (KPLTT100)
5/21/2026, 12:00:00 AM
Biogen and partner Denali Therapeutics announced that the Phase 2b LUMA study of their investigational Parkinson's disease drug, BIIB122, failed to meet its primary and secondary endpoints on May 21, 2026. Development for this indication will be discontinued. High importance is estimated as clinical trial failures for major indications typically result in significant market reaction exceeding 10%. Expected.
Korean Translation
바이오젠과 파트너사 데날리 테라퓨틱스가 2026년 5월 21일 파킨슨병 치료제 후보물질 BIIB122의 2b상 LUMA 임상이 1차 및 2차 평가변수를 충족하지 못했다고 발표함. 해당 적응증에 대한 개발은 중단될 예정임. 주요 임상 실패는 10% 이상의 주가 변동을 초래할 것으로 예상되므로 높은 중요도로 분류됨. 예상됨.
Related Recent Events
Apple Inc (AAPL) · Other
CEO Tim Cook is scheduled to transition to the role of Executive Chair, with John Ternus, current SVP of Hardware Engineering, becoming the new CEO on September 1, 2026, which analysts forecast will result in a ~5% price impact, scheduled.
9/1/2026, 12:00:00 AM
Cisco Systems Inc (CSCO) · Earnings Release
Cisco's Q4 FY2026 earnings release is scheduled for August 12, 2026, based on past reporting schedules; high volatility is expected.
8/12/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
AMD Q2 2026 earnings release and $11.2B revenue guidance (46% YoY growth); medium importance justified by estimated >=5% price impact scheduled.
8/4/2026, 12:00:00 AM
Amazon.com Inc (AMZN) · Earnings Release
Amazon's Q2 2026 earnings release is scheduled for July 30, 2026, where analysts forecast an EPS of approximately $1.81-$1.82. Medium importance is estimated as earnings releases typically trigger 5-10% price volatility forecasted.
7/30/2026, 12:00:00 AM
Comcast Corp (CMCSA) · Earnings Release
Comcast is scheduled to release its Q2 2026 earnings results on 2026-07-30. Analysts forecast earnings of approximately $0.99 per share. A price impact of ≥5% is estimated based on historical earnings volatility, scheduled.
7/30/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 financial results on July 30, 2026; a 1-5% impact is estimated as the market anticipates the report, scheduled.
7/30/2026, 12:00:00 AM